EP1534346A2 - Toluidinblau-o-arzneisubstanz und ihre verwendung fur die anfarbung in vivo und fur die chemotherapeutische behandlung von dysplastischem gewebe - Google Patents

Toluidinblau-o-arzneisubstanz und ihre verwendung fur die anfarbung in vivo und fur die chemotherapeutische behandlung von dysplastischem gewebe

Info

Publication number
EP1534346A2
EP1534346A2 EP02739681A EP02739681A EP1534346A2 EP 1534346 A2 EP1534346 A2 EP 1534346A2 EP 02739681 A EP02739681 A EP 02739681A EP 02739681 A EP02739681 A EP 02739681A EP 1534346 A2 EP1534346 A2 EP 1534346A2
Authority
EP
European Patent Office
Prior art keywords
tbo
product
composition
phenylenediamine
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02739681A
Other languages
English (en)
French (fr)
Other versions
EP1534346A4 (de
Inventor
Karl Okolotowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zila Inc
Original Assignee
Zila Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zila Inc filed Critical Zila Inc
Publication of EP1534346A2 publication Critical patent/EP1534346A2/de
Publication of EP1534346A4 publication Critical patent/EP1534346A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is an improvement upon the Toluidine Blue O compositions,
  • the present invention relates to novel biological stain diagnostic and/or chemotherapeutic compositions that are adapted for human in vivo application.
  • TBO Toluidine Blue O
  • the present invention pertains to new methods of manufacturing TBO compositions
  • the present invention further pertains to a new and improved method of HPLC
  • the present invention further pertains to in vivo methods of using such novel TBO
  • compositions to identify suspect dysplastic, i.e., abnormal, tissue are provided.
  • the present invention further pertains to in vivo methods of using such novel TBO compositions as a chemotherapeutic agent against cancerous or precancerous tissue.
  • the invention pertains to compositions, in vivo diagnostic methods of use thereof, therapeutic treatment methods of use thereof and processes for manufacture thereof, which are specially adapted for use as a chemotherapeutic agent
  • Squamous cell carcinomas usually begin as surface lesions with erythema and slight
  • erythroplasia which may be either carcinoma in-situ or invasive carcinoma. While often
  • these lesions should be biopsied to determine whether the tissue is malignant
  • leukoplakia are pure white. Of these, only 10% of them are
  • carcinoma in-situ or invasive carcinoma found to be carcinoma in-situ or invasive carcinoma.
  • the depth of the lesion corresponds to a decrease in the percent
  • Epithelial staining is known for facilitating the visual detection of abnormal epithelial cells, granules, denatured epithelial cells, or denatured granules.
  • TBO a dye
  • TBO can be used as a screening test and to locate cancer tissue because of its effectiveness in staining malignant
  • WIP Publication Number WO 01/64110 disclosed that TBO is an effective dye for selectively killing cancer cells. Subsequently, WIP O Publication Number WO 01/64255 Al disclosed that the compounds represented by either peak eight or peak six of the
  • indamine-thiosulfonic acid e.g., in the presence of zinc chloride at boiling temperature for
  • TBO complex e.g., as a TBO/ZnCl 2 complex
  • purification may be accomplished by repeated re-solution and re-precipitation
  • TBO compositions contained a number of impurities, as well as were limited in
  • Burkett made improvements, as described in United States Patents 6,086,852 and 6,194,573, to the
  • composition composition and the method for manufacturing, use, and analysis of TBO drug substances.
  • the present invention solves the above problem by providing TBO products that comprise a maximization of the fractions comprising peak eight and/or peak six, respectively.
  • the present invention is the most desirable composition for use in a method for
  • the closest prior art method for manufacturing TBO comprised the steps of: (1)
  • the present invention improves upon the previous method by first oxidizing a starting material in
  • the starting material may be either a combination or individually: N-dimethyl- -phenylenediamine and/or N.N-dimethyl- . -
  • phenylenediamine depending on which peak, peak eight or peak six, or a combination thereof, is desired as the dominant fraction in the final product.
  • compositions comprised predominantly of peak eight or six, or a combination
  • TBO product referred to as "TBO product".
  • composition comprised of peaks eight, seven, six, and five in the approximate ratios 33:5:5:1, respectively.
  • N-dimethyl-p-phenylenediamine as a starting material results in a TBO
  • demethylated product composition comprised of peaks six, five, three and two in the
  • composition of matter comprising TBO and its C-4-methyl
  • HPLC peaks representing said isomers to the combined areas of the peaks representing said N-demethylated derivatives being at least about 7 : 1.
  • composition has a ratio of the area of the HPLC peak
  • TBO represents TBO to the area of the peak representing its C-4-methyl regioisomer of at least about 6 : 1.
  • TBO comprises at least 73 % by weight of the total
  • the present invention concerns a new composition of matter, comprising the N-demethylated derivatives
  • composition reveals that the ratio of the combined areas of the HPLC peaks representing said N-demethylated derivatives to the combined areas of the peaks representing said further, N,N-
  • the composition has a ratio of the area of the HPLC peak
  • group at the C-2 position comprises at least 73% by weight of the total organic dye content of said composition.
  • the total organic dye content of said composition is comprised of a mixture of predominantly TBO and N-demethylated derivative having the ring methyl group at the C-2 position.
  • the described composition is important in a method for identification, as well as,
  • TBO product is employed in yet another embodiment of the invention.
  • the process for manufacturing TBO product includes the steps of: synthesizing an indamine, converting the indamine into an S-indaminyl thiosulfate, further oxidizing the S-
  • compositions of TBO product e.g. peak eight and/or six, is applied to cancer tissues to
  • present invention provides a method for producing the most pure composition of TBO yet manufactured. Consequently, the present invention provides a more pure staining dye for use
  • the improvement builds upon a known HPLC method for analysis of a TBO dye product, which includes: forming a TBO sample solution, forming a mobile phase comprising a water-
  • the improvement includes: (1) a
  • the mobile phase as a composition including an ion-pair reagent, and (2) forming a second mobile phase composition comprising 50% alcohol by volume.
  • Fig. 1 is a 290 nm HPLC chromatogram, depicting the peaks which are characteristic of the TBO product compositions of the present invention wherein N,N -dimethyl-/?- phenylenediamine is the starting material;
  • Fig. 2 is a 290 mn HPLC chromatogram, depicting the peaks which are characteristic of TBO product compositions previously noted for maximum isolation and production of
  • Fig. 3 is a process flow diagram, depicting the preferred embodiment of the invention
  • TBO products including the novel TBO product compositions of the present invention wherein N,N -dimethyl-/. -phenylenediamine is the starting material;
  • Fig. 4 is the chemical reaction resulting from Step 1 of the process for manufacturing the TBO composition, wherein N,N -dimethyl-/? -phenylenediamine is the starting material,
  • Fig. 5 is the chemical reaction resulting from Step 2 of the process for manufacturing the TBO composition, wherein NN-dimethyl-p-phenylenediamine is the starting material,
  • Fig. 6 is the chemical reaction resulting from Step 3 of the process for manufacturing the TBO composition, wherein N,N -dimethyl- . -phenylenediamine is the starting material,
  • a composition includes the fraction, designated as peak eight 10 (herein refe ⁇ ed to as "peak
  • the present invention concerns the manufacture, and eventual
  • peak eight 10 is produced more than peak seven 12 in a ratio of 6 : 1.
  • Peaks eight 10 and six 14 co ⁇ espond to the TBO, and corresponding N-demethylated derivative, respectively, and wherein the ring methyl group is at the C-2 position.
  • mixture with a light during photodynamic therapy is specific to particular cancer types, as
  • the incidence of light can be modified according to wavelength and/or intensity. Accordingly, one skilled in the art is
  • the procedure for manufacturing the present TBO composition is a modification of previously known methods for producing TBO products. More particularly, the modification
  • the process entails oxidizing a solution of NN-dimethyl-/.- phenylenediamine and o-toluidine with a stabilizing agent. Following oxidation, an acid is
  • S-indaminyl thiosulfate 40 is created.
  • the S-indaminyl thiosulfate 40 is then oxidized with an oxidizing agent, followed by the
  • Fig. 3 is provided as a reference for the following steps, labeled Steps 1 - 4, which
  • dimethyl-/. -phenylenediamine reaction mixture 20 should be maintained at ⁇ 10 °C and
  • o-Toluidine hydrochloride is prepared by slowly adding 6.3 grams of hydrochloric
  • reaction mixture 26 should be maintained at below -10
  • the reaction mixture includes indamine dihydrochloride and derivatives thereof.
  • hydrochloric acid is believed to be a suitable stabilizing agent for both the starting material (NN-dimethyl-/ phenylenediamine and/or N-
  • the preceding step describes the components N,N-dimethyl-/?-phenylenediamine dihydrochloride powder and o-toluidine hydrochloride solution in their respective stabilized forms by hydrochloric acid.
  • FIG. 4 A diagram of the chemical reaction described above in Step 1, is provided in Fig. 4 and demonstrates the reactants and product by their molecular forms.
  • Step #2 Synthesis of an S-indaminyl thiosulfate
  • An acid is made by preparing an aluminum sulfate solution 32, which in turn is
  • Acids other than aluminum sulfate hexadecahydrate, may also be
  • a complexing agent is prepared by making a zinc chloride solution 34, which in turn
  • An oxidizing agent is prepared by making 29.25 grams of dichromate solution 36,
  • solution 38 which in turn is prepared by adding 6.53 grams of sodium thiosulfate
  • nucleophile is slowly added to the indamine dihydrochloride reaction mixture 30 and sti ⁇ ed
  • the precipitate which forms consists of the S-indaminyl thiosulfate 40 and derivatives thereof.
  • sulfur-containing nucleophile may be used and substituted for a sodium thiosulfate solution
  • the S-indaminyl thiosulfate 40 is maintained below 10 °C. With an addition funnel, slowly (over 20 minutes) add an oxidizing agent to the S-indaminyl thiosulfate 40 and stir for
  • oxidizing agent preferably 27.0 grams of zinc chloride solution 46, prepared by adding 12.22 grams of zinc
  • the final reaction mixture contains TBO and C-4-methyl regioisomer, and derivatives thereof.
  • the present invention also encompasses an improved HPLC method for analysis of the improved composition.
  • the improved HPLC method for analysis more resolutely reveals
  • phenylenediamine is the starting material:
  • Figs. 1 and 2 are the respective chromatograms resulting from the improved HPLC method of analysis disclosed, herein, and an analysis of a previously known HPLC method of
  • This laboratory method describes the assay procedure for the detection and quantification
  • the ion-pair reagent especially facilitates the separation of TBO compositions.
  • heptanesulfonic acid, sodium salt may facilitate the separation of other
  • a second mobile phase including an alcohol and a mobile phase solvent in a 50:50
  • Another important improvement includes an adjusted flow rate to 1.0 mL/min., from
  • HPLC method include: purified water, mobile phase solvent (e.g. HPLC grade acetonitrile
  • ACN a buffer salt
  • reagent grade acid e.g. glacial acetic acid
  • reagent grade base e.g. ammonium hydroxide (NH 4 OH)
  • Mobile Phase A is typically prepared by mixing a suitable buffer salt with H 2 O and
  • Mobile Phase B is typically prepared by adding equal volumes of a mobile phase solvent
  • diluent is not limited to comprising ACN, but that various mobile phase solutions known in the
  • a quality control standard sample is prepared by making a 0.15 mg/mL sample solution in
  • the tailing factor for any active peak (five 16, six 14, seven 12, and eight 10) should be less than or
  • the second standard must be between 97.0 and 103.0% of the theoretical
  • the relative retention time (RRT) of the TBO product mixture's peaks in the sample preparation should co ⁇ espond to the relative retention time of the TBO product mixture active peaks
  • C n Concentration in mg/mL, of TBO in the Standard preparation.
  • R. td Average peak five 16 area of TBO in the Standard preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
EP02739681A 2002-06-04 2002-06-04 Toluidinblau-o-arzneisubstanz und ihre verwendung fur die anfarbung in vivo und fur die chemotherapeutische behandlung von dysplastischem gewebe Withdrawn EP1534346A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/017720 WO2003103569A2 (en) 2002-06-04 2002-06-04 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues

Publications (2)

Publication Number Publication Date
EP1534346A2 true EP1534346A2 (de) 2005-06-01
EP1534346A4 EP1534346A4 (de) 2007-07-25

Family

ID=29731309

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02739681A Withdrawn EP1534346A4 (de) 2002-06-04 2002-06-04 Toluidinblau-o-arzneisubstanz und ihre verwendung fur die anfarbung in vivo und fur die chemotherapeutische behandlung von dysplastischem gewebe

Country Status (9)

Country Link
EP (1) EP1534346A4 (de)
JP (1) JP2005535605A (de)
CN (1) CN1302815C (de)
AU (1) AU2002312319A1 (de)
BR (1) BRPI0215775A2 (de)
IL (1) IL165516A0 (de)
MX (1) MXPA04012031A (de)
TW (1) TW200733956A (de)
WO (1) WO2003103569A2 (de)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH071257B2 (ja) * 1985-09-09 1995-01-11 エスエス製薬株式会社 混合ビタミン剤中の水溶性ビタミン類の同時定量法
JPS6410171A (en) * 1987-07-03 1989-01-13 Shimadzu Corp Analysis of amino acid
CA2097695C (en) * 1991-10-31 2000-08-08 Mark J. Malmros Biological stain composition, method of preparation and method of use for delineation of epithelial cancer
WO1999025388A1 (en) * 1997-11-13 1999-05-27 Zila, Inc. In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue
US6086852A (en) * 1997-11-13 2000-07-11 Zila, Inc. In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue
US6194573B1 (en) * 1997-11-13 2001-02-27 Zila, Inc. Process for manufacture of in vivo stain composition
WO2001064110A1 (en) * 2000-02-28 2001-09-07 Zila, Inc. Method for detecting and killing epithelial cancer cells
JP4424838B2 (ja) * 2000-08-31 2010-03-03 株式会社トクヤマ 四級アンモニウム塩の分析方法

Also Published As

Publication number Publication date
BRPI0215775A2 (pt) 2016-07-05
AU2002312319A1 (en) 2003-12-22
TW200733956A (en) 2007-09-16
CN1627961A (zh) 2005-06-15
MXPA04012031A (es) 2005-03-07
EP1534346A4 (de) 2007-07-25
WO2003103569A3 (en) 2004-05-21
JP2005535605A (ja) 2005-11-24
WO2003103569A2 (en) 2003-12-18
CN1302815C (zh) 2007-03-07
IL165516A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
TWI518089B (zh) 實質上純質之螢光素
CN111548790A (zh) 一种近红外比率型荧光探针及其合成方法与应用
CN109180556A (zh) 一种部花菁类荧光化合物及其制备方法和应用
US6086852A (en) In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue
CN101118236A (zh) 检测细胞内氢离子的近红外荧光探针及其合成方法和用途
JPH11209357A (ja) 形成異常の組織を確認するための生体内における染色組成物、その製造方法および使用方法
WO2010054330A2 (en) Monofunctional carbocyanine dyes for in vivo and in vitro imaging
US20060110326A1 (en) Toluidine blue o drug substance and use thereof for in vitro staining and chemotherapeutic treatment of dysplastic tissues
WO2003103569A2 (en) Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
US11857644B2 (en) Multi-signal fluorescent probe for early diagnosis of tumors, and preparation and use thereof
CN120059488A (zh) 近红外二区白蛋白高效原位靶向的花菁染料及其制备方法和应用
NZ537344A (en) Toluidine blue O drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
US20250224399A1 (en) Method for detecting homocysteine in plasma and method for diagnosing glioblastoma by using novel fluorescent probe
US12480948B2 (en) Ratiometric fluorescent probe for detecting aminopeptidase N, and preparation method and use thereof
KR20050044769A (ko) 톨루이딘 블루 o 약물, 및 형성이상 조직의 생체내 염색및 화학요법적 치료에서의 이들의 용도
US20230105273A1 (en) Novel compound or salt thereof, composition for cysteine detection, fluorescent probe and composition for diagnosing cancer containing the same, method for detecting cysteine, method for providing information for diagnosing cancer, and method for producing novel compound
CN117143056B (zh) 一种近红外二区荧光/光声双模态成像gsh探针及其制备方法和应用
AU784639B2 (en) In vivo stain compounds and methods of use to identify dysplastic tissue
CN119707920B (zh) 一种检测nadh的荧光探针及其制备方法与应用
CN119954825A (zh) 一种生物素受体靶向化合物、其制备方法与应用
CN118026917A (zh) 检测过氧亚硝酰的苯并花菁衍生物及其制备方法和应用
AU8945698A (en) In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue
CN121574116A (zh) 一种细胞核靶向黄色荧光探针及其制备方法与应用
CN120398865A (zh) 一种荧光探针及其制备方法与应用
EA002127B1 (ru) Композиция для окрашивания in vivo, способ ее получения и способы ее применения для идентификации диспластической ткани

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050104

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070621

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5415 20060101AFI20070615BHEP

Ipc: A61K 49/00 20060101ALI20070615BHEP

Ipc: A61K 41/00 20060101ALI20070615BHEP

17Q First examination report despatched

Effective date: 20071022

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100903